Home Stock

Stock Research: Collegium Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Collegium Pharmaceutical

NSQ:COLL US19459J1043
47
  • Value
    84
  • Growth
    44
  • Safety
    Safety
    13
  • Combined
    43
  • Sentiment
    57
  • 360° View
    360° View
    47
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on products for ADHD and moderate to severe pain. It operates in the biopharmaceutical industry, with commercial products including Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR, and Symproic, primarily in the United States. In the last fiscal year, the company had a market cap of $1,030 million, profits of $377 million, revenue of $631 million, and 357 employees.

more

ANALYSIS: With an Obermatt 360° View of 47 (better than 47% compared with alternatives), overall professional sentiment and financial characteristics for the stock Collegium Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Collegium Pharmaceutical. The consolidated Value Rank has an attractive rank of 84, which means that the share price of Collegium Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 84% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 44, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 13, meaning the company has a riskier financing structure than 87 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Medium
Website collegiumpharma.com
Index
NASDAQ
Collegium Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 63 37 77
Growth
44 65 63 43
Safety
Safety
13 18 25 40
Sentiment
57 82 89 39
360° View
360° View
47 62 56 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
34 75 58 1
Opinions Change
50 50 50 50
Pro Holdings
n/a 88 85 100
Market Pulse
28 51 75 38
Sentiment
57 82 89 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 63 37 77
Growth
44 65 63 43
Safety Safety
13 18 25 40
Combined
43 35 22 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
88 66 58 66
Price vs. Earnings (P/E)
42 96 71 100
Price vs. Book (P/B)
64 23 6 44
Dividend Yield
1 1 1 1
Value
84 63 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
36 70 27 23
Profit Growth
89 100 100 98
Capital Growth
25 14 18 35
Stock Returns
46 45 77 49
Growth
44 65 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
7 12 15 36
Refinancing
12 10 27 31
Liquidity
60 61 59 71
Safety Safety
13 18 25 40

Similar Stocks

Discover high‑ranked alternatives to Collegium Pharmaceutical and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Humana

NYQ:HUM
Country: USA
Industry: Health Care Managed
Size: Large
Full Stock Analysis

Stewart Information

NYQ:STC
Country: USA
Industry: Property & Casualty Insurance
Size: Medium
Full Stock Analysis

Revvity

NYQ:RVTY
Country: USA
Industry: Life Sciences Tools & Services
Size: Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews